Compared to that of control tumors, TAMs in ASH1L-depleted bone tumors showed significant elevation in inflammation pathways, including IFN signaling, TNF signaling, IL-1/2 signaling, cGAS-STING, and antigen processing and presentation pathway (Fig. 6a). This evidence concerns the gene ASH1L and bone neoplasm.